+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Prolactin receptor antagonists



Prolactin receptor antagonists



Endocrine 9(2): 121-131



Most prolactin (PRL) in the circulation is produced by the pituitary. However, a wide variety of traditional target tissues of the hormone have also been shown to produce their own prolactin. The amount produced per cell is low, but may well be sufficient for autocrine/paracrine activity. Although dopamine agonists allow one to study the target tissue effects of pituitary PRL, other agents, such as PRL receptor (PRLR) antagonists, are needed to analyze autocrine/paracrine loops. With PRLR antagonists, it should be possible to dissect out the role of extrapituitary prolactin in both the normal physiology, and the pathophysiology of various tissues. in tissues where the locally produced PRL may promote disease, such antagonists have the potential to be important therapeutics. This article briefly, but critically, reviews current understanding of PRL-receptor interactions and initial signaling, and describes the development of both growth hormone (GH) and PRL antagonists within that context. In the final section, results with a very potent PRL antagonist further one theme of the article, which is whether the simple receptor dimerization model explains all signal transduction following PRLR binding.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 011209068

Download citation: RISBibTeXText

PMID: 9867245

DOI: 10.1385/endo:9:2:121


Related references

Prolactin increases survival and migration of ovarian cancer cells: importance of prolactin receptor type and therapeutic potential of S179D and G129R receptor antagonists. Cancer Letters 310(1): 101-108, 2011

Development of new prolactin analogs acting as pure prolactin receptor antagonists. Pituitary 6(2): 89-95, 2003

Development of prolactin receptor antagonists with reduced pH-dependence of receptor binding. Journal of Molecular Recognition 24(4): 533-547, 2011

A comparison of two semi-mechanistic models for prolactin release and prediction of receptor occupancy following administration of dopamine D2 receptor antagonists in rats. European Journal of Pharmacology 789: 202-214, 2016

Development of pure prolactin receptor antagonists. Journal of Biological Chemistry 278(38): 35988-35999, 2003

Prolactin responses to histamine H2 receptor antagonists. Acta Endocrinologica 95(3): 308-313, 1980

Effect of 5-HT-1A receptor antagonists on the secretion of ACTH and prolactin. Society for Neuroscience Abstracts 23(1-2): 2049, 1997

Mechanism-based design of prolactin receptor antagonists. Journal of Biological Chemistry 268(8): 5376-5381, 1993

Different effects of 2 histamine h 2 receptor antagonists on prolactin secretion in man. Acta Endocrinologica Suppl. 94(234): 4, 1980

Identification of JAK protein tyrosine kinases as signaling molecules for prolactin: Functional analysis of prolactin receptor and prolactin: Erythropoietin receptor chimera expressed in lymphoid cells. EMBO (European Molecular Biology Organization) Journal 13(11): 2583-2591, 1994

Histamine h 2 receptor antagonists and prolactin secretion in male rats. Acta Physiologica Scandinavica 123(2): 10A, 1985

Comparison of the effects of histamine H2-receptor antagonists on prolactin secretion in the rat. Endocrinology 113(1): 412-414, 1983

Development and potential clinical uses of human prolactin receptor antagonists. Endocrine Reviews 26(3): 400-422, 2005